Welcome to LookChem.com Sign In|Join Free

CAS

  • or

23255-32-5

23255-32-5

Post Buying Request

23255-32-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

23255-32-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 23255-32-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,3,2,5 and 5 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 23255-32:
(7*2)+(6*3)+(5*2)+(4*5)+(3*5)+(2*3)+(1*2)=85
85 % 10 = 5
So 23255-32-5 is a valid CAS Registry Number.
InChI:InChI=1/C6H13NO4S/c8-2-4(9)1-7-5(3-12)6(10)11/h4-5,7-9,12H,1-3H2,(H,10,11)/t4?,5-/m0/s1

23255-32-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name (2R)-2-(2,3-dihydroxypropylamino)-3-sulfanylpropanoic acid

1.2 Other means of identification

Product number -
Other names Alanine,3-[(2,3-dihydroxypropyl)thio]-,L-(8CI)

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:23255-32-5 SDS

23255-32-5Downstream Products

23255-32-5Relevant articles and documents

ADMINISTRATION OF A TLR2 AGONIST FOR THE TREATMENT OR PREVENTION OF A RESPIRATORY CONDITION ASSOCIATED WITH AN INFECTIOUS AGENT

-

Page/Page column 95; 96, (2019/07/13)

The present invention relates to methods of treating or preventing respiratory conditions. In particular, the methods relate to treatment of respiratory conditions associated with a virus, such as influenza. In particular, the present invention provides a method of treating or preventing a respiratory condition associated with an infectious agent in an individual, the method comprising administering a compound comprising a TLR2 agonist to the upper respiratory tract of the individual, thereby treating or preventing a respiratory condition associated with an infectious agent in the individual. The compound is not administered to the lower respiratory tract or to both the upper and lower respiratory tract (i.e. administered to the total respiratory tract).

Structure and synthesis of an immunoactive lipopeptide, WS1279, of microbial origin

Tsuda,Okada,Tanaka,Shigematsu,Hori,Goto,Hashimoto

, p. 607 - 611 (2007/10/02)

-

S-carboxymethylcysteine synthase from Escherichia coli

Kumagai,Suzuki,Shigematsu,Tochikura

, p. 2481 - 2487 (2007/10/02)

-

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 23255-32-5